美国白宫：美国总统特朗普已下令美国食品药品监督管理局（FDA）加强对外国药品生产商主动药用原料来源报告的执法力度，并考虑公开展示不合规药厂的名单。

Core Viewpoint - The U.S. government, under President Trump, has directed the FDA to enhance enforcement regarding the reporting of active pharmaceutical ingredient sources by foreign drug manufacturers and is considering publicly listing non-compliant drug manufacturers [1] Group 1 - The FDA will increase its enforcement actions against foreign pharmaceutical manufacturers [1] - There is a potential plan to publicly disclose a list of non-compliant drug manufacturers [1]